

## Contents

### List of Contributors XVII

|           |                                                           |          |
|-----------|-----------------------------------------------------------|----------|
| <b>1</b>  | <b>Protection Reactions</b>                               | <b>1</b> |
|           | <i>Vommina V. Sureshbabu and Narasimhamurthy Narendra</i> |          |
| 1.1       | General Considerations                                    | 1        |
| 1.2       | $\alpha$ -Amino Protection ( $N^\alpha$ Protection)       | 4        |
| 1.2.1     | Non-Urethanes                                             | 4        |
| 1.2.1.1   | Acyl Type                                                 | 4        |
| 1.2.1.1.1 | Monoacyl Groups                                           | 5        |
| 1.2.1.1.2 | Groups Cleavable via Lactam Formation                     | 6        |
| 1.2.1.1.3 | Diacyl Groups                                             | 7        |
| 1.2.1.2   | Phosphine-Type Groups                                     | 10       |
| 1.2.1.3   | Sulfonyl-Type Groups                                      | 10       |
| 1.2.1.4   | Alkyl-Type Groups                                         | 11       |
| 1.2.1.4.1 | Triphenylmethyl (Trityl or Trt) Group                     | 11       |
| 1.2.1.4.2 | Benzhydryl Groups                                         | 12       |
| 1.2.1.4.3 | <i>N,N</i> -Bis-Benzyl Protection                         | 12       |
| 1.2.1.4.4 | Vinyl Groups                                              | 12       |
| 1.2.1.5   | Sulfanyl-Type Groups                                      | 13       |
| 1.2.2     | Urethanes (Carbamates or Alkylloxycarbonyl Groups)        | 14       |
| 1.2.2.1   | Formation of the Urethane Bond                            | 16       |
| 1.2.2.2   | Urethanes Derived from Primary Alcohols                   | 16       |
| 1.2.2.2.1 | Benzyloxycarbonyl (Cbz or Z) Group                        | 16       |
| 1.2.2.2.2 | Urethanes Cleaved by $\beta$ -Elimination                 | 19       |
| 1.2.2.2.3 | Urethanes Cleaved via Michael-Type Addition               | 24       |
| 1.2.2.2.4 | Allyloxycarbonyl (Aloc) Group                             | 25       |
| 1.2.2.3   | Urethane Groups Derived from Secondary Alcohols           | 25       |
| 1.2.2.4   | Urethanes Derived from Tertiary Alcohols                  | 25       |
| 1.2.2.4.1 | <i>tert</i> -Butoxycarbonyl (Boc) Group                   | 25       |
| 1.2.2.4.2 | Boc Analogs                                               | 28       |
| 1.2.2.5   | Other Aspects of Urethane Protectors                      | 29       |

|           |                                                                                                           |    |
|-----------|-----------------------------------------------------------------------------------------------------------|----|
| 1.2.2.5.1 | Formation of Dipeptide Impurities during the Introduction of Urethanes and Protocols to Overcome It       | 29 |
| 1.2.2.5.2 | Introduction of Urethanes via Transprotection                                                             | 30 |
| 1.2.2.5.3 | Protection of the Nitrogen of $\alpha$ -Amino Acid <i>N</i> -Carboxy Anhydrides (NCAs)                    | 31 |
| 1.2.2.5.4 | $N^\alpha$ - $N^\alpha$ -bis-Protected Amino Acids                                                        | 32 |
| 1.2.3     | Other $N^\alpha$ -Protecting Groups                                                                       | 32 |
| 1.2.3.1   | $\alpha$ -Azido Acids as $\alpha$ -Amino Acid Precursors                                                  | 33 |
| 1.2.3.2   | One-Pot $N^\alpha$ Protection and $C^\alpha$ Activation                                                   | 33 |
| 1.2.3.3   | Effect of $N^\alpha$ -Protecting Groups in the Synthesis of NMAs                                          | 33 |
| 1.3       | Carboxy Protection                                                                                        | 34 |
| 1.3.1     | Methyl and Ethyl Esters                                                                                   | 35 |
| 1.3.1.1   | Substituted Methyl and Ethyl Esters                                                                       | 36 |
| 1.3.2     | Benzyl Ester                                                                                              | 36 |
| 1.3.2.1   | Cleavage                                                                                                  | 36 |
| 1.3.3     | Substituted Benzyl Esters                                                                                 | 38 |
| 1.3.4     | <i>tert</i> -Butyl Ester                                                                                  | 38 |
| 1.3.5     | Other Acid-Labile Esters                                                                                  | 39 |
| 1.3.6     | Temporary $\alpha$ -Carboxy Protection                                                                    | 39 |
| 1.3.7     | $\alpha$ -Carboxy Protectors as Precursors to Useful Amino Acid Derivatives: Formation of Acid Hydrazides | 41 |
| 1.4       | Side-Chain Protection                                                                                     | 41 |
| 1.4.1     | $\omega$ -Amino Group of Diamino Acids                                                                    | 41 |
| 1.4.2     | Guanidino Group of Arg                                                                                    | 43 |
| 1.4.2.1   | Protection Through Protonation                                                                            | 43 |
| 1.4.2.2   | Nitration                                                                                                 | 44 |
| 1.4.2.3   | Arg Precursors                                                                                            | 45 |
| 1.4.3     | Imidazole Group of His                                                                                    | 45 |
| 1.4.4     | Indole Group of Trp                                                                                       | 48 |
| 1.4.5     | $\omega$ -Amido Group of Asn and Gln                                                                      | 49 |
| 1.4.6     | $\beta$ -Thiol Group of Cys                                                                               | 50 |
| 1.4.6.1   | Common Side-Reactions with S-Protected Cys Derivatives                                                    | 51 |
| 1.4.6.1.1 | Racemization                                                                                              | 51 |
| 1.4.6.1.2 | $\beta$ -Elimination                                                                                      | 51 |
| 1.4.6.1.3 | Oxidation                                                                                                 | 51 |
| 1.4.6.2   | Synthesis of Peptides Using Cystine as "Self-Protected" Cys                                               | 51 |
| 1.4.7     | Thioether Group of Met                                                                                    | 53 |
| 1.4.8     | Hydroxy Group of Ser, Thr, and the Phenolic Group of Tyr                                                  | 54 |
| 1.4.9     | $\omega$ -Carboxy Group of Asp and Glu                                                                    | 55 |
| 1.4.9.1   | Aspartimide Formation                                                                                     | 55 |
| 1.5       | Photocleavable Protections                                                                                | 57 |
| 1.6       | Conclusions                                                                                               | 58 |
| 1.7       | Experimental Procedures                                                                                   | 59 |
| 1.7.1     | Protection Reactions                                                                                      | 59 |
| 1.7.1.1   | General Procedure for the Preparation of Tfa-Arg-OH                                                       | 59 |

|            |                                                                                                                           |    |
|------------|---------------------------------------------------------------------------------------------------------------------------|----|
| 1.7.1.2    | General Procedure for the Preparation of $N^\alpha$ -Phthaloyl Amino Acids using <i>N</i> -(Ethoxycarbonyl)phthalimide    | 59 |
| 1.7.1.3    | General Procedure for the Preparation of $N^\alpha$ -Trt-Amino Acids                                                      | 59 |
| 1.7.1.4    | General Procedure for the Preparation of $N^\alpha$ -Ns-Amino Acids                                                       | 60 |
| 1.7.1.5    | General Procedure for the Preparation of $N^\alpha$ -Z-Amino Acids                                                        | 61 |
| 1.7.1.5.1  | Method A: Using Z-Cl                                                                                                      | 61 |
| 1.7.1.5.2  | Method B: Using Z-OSu                                                                                                     | 62 |
| 1.7.1.6    | General Procedures for the Preparation of $N^\alpha$ -Fmoc-Amino Acids                                                    | 62 |
| 1.7.1.6.1  | Method A: Using Fmoc-OSu                                                                                                  | 62 |
| 1.7.1.6.2  | Method B: Using Fmoc-Cl and <i>N,O</i> -bis-TMS-Amino Acids                                                               | 62 |
| 1.7.1.6.3  | Method C: Using Fmoc-Cl in the Presence of Zinc Dust                                                                      | 63 |
| 1.7.1.6.4  | Method D: Using Fmoc- $N_3$                                                                                               | 63 |
| 1.7.1.7    | General Procedure for the Preparation of $N^\alpha$ -Nsc-Amino Acids                                                      | 64 |
| 1.7.1.8    | General Procedure for the Preparation of $N^\alpha$ -Bsmoc-Amino Acids                                                    | 64 |
| 1.7.1.9    | General Procedure for the Preparation of $N^\alpha$ -Aloc-Amino Acids                                                     | 65 |
| 1.7.1.10   | General Procedures for the Preparation of $N^\alpha$ -Boc-Amino Acids                                                     | 65 |
| 1.7.1.10.1 | Method A: Using (Boc) $_2$ O                                                                                              | 65 |
| 1.7.1.10.2 | Method B: Using Boc-ON                                                                                                    | 65 |
| 1.7.1.10.3 | Method C: Using Boc- $N_3$                                                                                                | 66 |
| 1.7.1.11   | General Procedure for the Preparation of <i>N,N'</i> -di-Boc-Amino Acids                                                  | 66 |
| 1.7.1.12   | General Procedure for the Preparation of $N^\alpha$ -Bpoc-Amino Acids                                                     | 67 |
| 1.7.1.13   | General Procedures for the Preparation of Amino Acid Methyl Esters                                                        | 68 |
| 1.7.1.13.1 | Preparation of Amino Acid Methyl Ester Hydrochloride Salts                                                                | 68 |
| 1.7.1.13.2 | Isolation of Amino Acid Methyl Esters: Deprotonation of the Hydrochloride Salt Using Zinc Dust                            | 69 |
| 1.7.1.13.3 | Glutamic Acid $\alpha$ -Methyl, $\gamma$ - <i>tert</i> -Butyl Diester Using Diazomethane                                  | 69 |
| 1.7.1.13.4 | Z-Glu-OMe via Methanolysis of Cyclic Anhydride                                                                            | 69 |
| 1.7.1.14   | General Procedure for the Preparation of Amino Acid Ethyl Esters                                                          | 69 |
| 1.7.1.15   | General Procedure for the Preparation of Amino Acid Benzyl Ester <i>p</i> -Toluenesulfonate Salts                         | 70 |
| 1.7.1.15.1 | Preparation of Amino Acid Benzyl Ester <i>p</i> -Toluenesulfonate Salts Under Microwave Irradiation                       | 70 |
| 1.7.1.16   | General Procedure for the Preparation of <i>tert</i> -Butyl Esters of $N^\alpha$ -Unprotected Amino Acids Using Isobutene | 71 |
| 1.7.1.16.1 | Preparation of Z-Phe-O <i>t</i> Bu by the Silver Salt Method                                                              | 71 |
| 1.7.1.17   | General Procedure for Concomitant Protection and Activation of Amino Acids Using Pentafluorophenyl Carbonate              | 80 |

|           |                                                                                            |    |
|-----------|--------------------------------------------------------------------------------------------|----|
| 1.7.2     | Deprotection Reactions                                                                     | 81 |
| 1.7.2.1   | Removal of the Phth Group by Hydrazinolysis                                                | 81 |
| 1.7.2.2   | Removal of the Nps Group                                                                   | 81 |
| 1.7.2.3   | Removal the Z-group                                                                        | 82 |
| 1.7.2.3.1 | Protocol A: Employing CH                                                                   | 82 |
| 1.7.2.3.2 | Protocol B: Employing Silylhydride                                                         | 82 |
| 1.7.2.3.3 | Protocol C: Through CTH using 1,4-Cyclohexadieneas<br>Hydrogen Donor                       | 83 |
| 1.7.2.4   | Cleavage of the Fmoc Group                                                                 | 83 |
| 1.7.2.4.1 | Method A: Using TAEA [67]                                                                  | 83 |
| 1.7.2.4.2 | Method B: Using DEA: Simultaneous Removal of the Fmoc Group<br>and 9-Fluorenylmethyl Ester | 83 |
| 1.7.2.5   | Cleavage of the Boc Group                                                                  | 84 |
| 1.7.2.5.1 | Protocol A: Removal of the Boc group with TFA<br>in the Presence of Scavengers             | 84 |
| 1.7.2.5.2 | Protocol B: Cleavage of Boc Group with<br>TMS/Phenol                                       | 84 |
| 1.7.2.6   | Transprotection of $N^{\alpha}$ -Protecting Groups:<br>Fmoc-Met-OH to Boc-Met-OH           | 84 |
| 1.7.2.7   | Selective Methyl Ester Hydrolysis in the Presence<br>of the $N^{\alpha}$ -Fmoc Group       | 84 |
| 1.7.2.8   | Cleavage of <i>tert</i> -Butyl Ester Using $\text{BF}_3 \cdot \text{Et}_2\text{O}$         | 84 |
| 1.7.2.9   | Selective Cleavage of Phenacyl Ester in the<br>Presence of the $N^{\alpha}$ -Nosyl Group   | 85 |
| 1.7.2.10  | Removal of the Trt Group (Iodolysis)                                                       | 85 |
| 1.7.2.11  | Deprotection of the Pbf Group from Z-Arg(Pbf)-OH                                           | 85 |
| 1.7.2.12  | Removal of the Phenoc Group through Photolysis                                             | 85 |
| 1.7.2.13  | Conversion of the DCHA Salt of $N^{\alpha}$ -Protected Amino Acids<br>into Free Acids      | 85 |
|           | References                                                                                 | 86 |

## Part One Amino Acid-Based Peptidomimetics 99

|          |                                                                               |            |
|----------|-------------------------------------------------------------------------------|------------|
| <b>2</b> | <b>Huisgen Cycloaddition in Peptidomimetic Chemistry</b>                      | <b>101</b> |
|          | <i>Daniel Sejer Pedersen and Andrew David Abell</i>                           |            |
| 2.1      | Introduction                                                                  | 101        |
| 2.2      | Huisgen [2 + 3] Cycloaddition Between Azides and<br>Acetylenes                | 102        |
| 2.3      | Mechanistic Consideration for the Cu-Huisgen<br>and Ru-Huisgen Cycloadditions | 103        |
| 2.4      | Building Blocks for the Synthesis of Triazole-Modified<br>Peptidomimetics     | 106        |
| 2.5      | Cyclic Triazole Peptidomimetics                                               | 109        |
| 2.6      | Acyclic Triazole Peptidomimetics                                              | 113        |
| 2.7      | Useful Experimental Procedures                                                | 121        |

|                 |                                                                                              |            |
|-----------------|----------------------------------------------------------------------------------------------|------------|
| 2.7.1           | Monitoring Huisgen Cycloadditions and Characterizing Triazoles                               | 121        |
| 2.7.2           | General Procedure for the Synthesis of 1,4-Triazoles Using Cu-Huisgen Cycloaddition          | 122        |
| 2.7.3           | General Procedure for the Synthesis of 1,5-Triazoles Using Ru-Huisgen Cycloaddition          | 123        |
|                 | References                                                                                   | 124        |
| <b>3</b>        | <b>Recent Advances in <math>\beta</math>-Strand Mimetics</b>                                 | <b>129</b> |
|                 | <i>Wendy A. Loughlin and David P. Fairlie</i>                                                |            |
| 3.1             | Introduction                                                                                 | 129        |
| 3.1.1           | $\beta$ -Strands                                                                             | 129        |
| 3.1.2           | $\beta$ -Sheets                                                                              | 130        |
| 3.1.3           | Differences in Strand/Sheet/Turn/Helix Recognition                                           | 130        |
| 3.1.4           | Towards $\beta$ -Strand Mimetics                                                             | 131        |
| 3.2             | Macrocyclic Peptidomimetics                                                                  | 133        |
| 3.3             | Acyclic Compounds                                                                            | 135        |
| 3.4             | Aliphatic and Aromatic Carbocycles                                                           | 136        |
| 3.5             | Ligands Containing One Ring with One Heteroatom (N)                                          | 137        |
| 3.6             | Ligands Containing One or Multiple Rings with One Heteroatom (O, S)                          | 138        |
| 3.7             | Ligands Containing One Ring with Two Heteroatoms (N,N)                                       | 139        |
| 3.8             | Ligands Containing One Ring with Two Heteroatoms (N,S) or Three Heteroatoms (N,N,S or N,N,N) | 140        |
| 3.9             | Ligands Containing Two Rings with One Heteroatom (N or O)                                    | 140        |
| 3.10            | Ligands Containing Two Rings with Two or Three Heteroatoms (N,N or N,S or N,N,N)             | 141        |
| 3.11            | Conclusions                                                                                  | 142        |
|                 | References                                                                                   | 143        |
| <b>Part Two</b> | <b>Medicinal Chemistry of Amino Acids</b>                                                    | <b>149</b> |
| <b>4</b>        | <b>Medicinal Chemistry of <math>\alpha</math>-Amino Acids</b>                                | <b>151</b> |
|                 | <i>Lennart Bunch and Povl Krosgaard-Larsen</i>                                               |            |
| 4.1             | Introduction                                                                                 | 151        |
| 4.2             | Glutamic Acid                                                                                | 151        |
| 4.3             | Conformational Restriction                                                                   | 153        |
| 4.3.1           | Synthesis – General Considerations                                                           | 154        |
| 4.3.2           | Case Study: Synthesis of DCAN                                                                | 155        |
| 4.3.3           | Case Study: Synthesis of LY354740                                                            | 157        |
| 4.3.4           | Case Study: Synthesis of ABHD-V and ABHD-VI                                                  | 158        |
| 4.4             | Bioisosterism                                                                                | 159        |
| 4.4.1           | Case Study: Design and Synthesis of AMPA                                                     | 160        |
| 4.4.2           | Case Study: Design and Synthesis of Thioibotenic Acid                                        | 161        |
| 4.5             | Structure–Activity Studies                                                                   | 162        |

|          |                                                                                          |            |
|----------|------------------------------------------------------------------------------------------|------------|
| 4.5.1    | Case Study: AMPA Analogs                                                                 | 162        |
| 4.5.2    | Case Study: 4-Substituted Glu analogs                                                    | 163        |
| 4.6      | Conclusions                                                                              | 168        |
|          | References                                                                               | 169        |
| <b>5</b> | <b>Medicinal Chemistry of Alicyclic <math>\beta</math>-Amino Acids</b>                   | <b>175</b> |
|          | <i>Nils Griebenow</i>                                                                    |            |
| 5.1      | Introduction                                                                             | 175        |
| 5.2      | Five-Membered Alicyclic $\beta$ -Amino Acids                                             | 175        |
| 5.3      | Six-Membered Alicyclic $\beta$ -Amino Acids                                              | 183        |
|          | References                                                                               | 186        |
| <b>6</b> | <b>Medicinal Chemistry of <math>\alpha</math>-Hydroxy-<math>\beta</math>-Amino Acids</b> | <b>189</b> |
|          | <i>Zyta Ziora, Mariusz Skwarczynski, and Yoshiaki Kiso</i>                               |            |
| 6.1      | Introduction                                                                             | 189        |
| 6.2      | $\alpha$ -Hydroxy- $\beta$ -Amino Acids                                                  | 189        |
| 6.2.1    | $\alpha$ -Hydroxy- $\beta$ -Amino Acids Occurring in Natural Products                    | 189        |
| 6.2.2    | Synthesis of $\alpha$ -Hydroxy- $\beta$ -Amino Acids                                     | 191        |
| 6.2.2.1  | Isoserine                                                                                | 191        |
| 6.2.2.2  | Isothreonine                                                                             | 193        |
| 6.2.2.3  | Phenylisoserine                                                                          | 197        |
| 6.2.2.4  | Norstatines                                                                              | 197        |
| 6.2.2.5  | 3-Amino-2-Hydroxydecanoic Acid and its Analogs                                           | 204        |
| 6.2.2.6  | Synthetic Demands                                                                        | 205        |
| 6.3      | Antibacterial Agents                                                                     | 205        |
| 6.4      | Inhibitors of Aminopeptidases                                                            | 207        |
| 6.5      | Aspartyl Proteases Inhibitors                                                            | 211        |
| 6.5.1    | Renin Inhibitors                                                                         | 212        |
| 6.5.2    | HIV-1 Protease Inhibitors                                                                | 216        |
| 6.5.3    | HTLV-I Inhibitors                                                                        | 220        |
| 6.5.4    | Plasmepsin II Inhibitors                                                                 | 222        |
| 6.5.5    | BACE-1 Inhibitors                                                                        | 224        |
| 6.6      | Paclitaxel and its Derivatives                                                           | 228        |
|          | References                                                                               | 234        |
| <b>7</b> | <b>Peptide Drugs</b>                                                                     | <b>247</b> |
|          | <i>Chiara Falciani, Alessandro Pini, and Luisa Bracci</i>                                |            |
| 7.1      | Lights and Shades of Peptide and Protein Drugs                                           | 247        |
| 7.2      | Peptide Drugs Available on the Market                                                    | 249        |
| 7.2.1    | Natriuretic Peptide (Nesiritide)                                                         | 249        |
| 7.2.2    | Oxytocin                                                                                 | 249        |
| 7.2.3    | Vasopressin                                                                              | 250        |
| 7.2.4    | Desmopressin                                                                             | 251        |
| 7.2.5    | Blood Coagulation Inhibitors                                                             | 251        |
| 7.2.5.1  | Bivalirudin                                                                              | 251        |

|          |                                                                                       |            |
|----------|---------------------------------------------------------------------------------------|------------|
| 7.2.5.2  | Integrilin (Eptifibatide)                                                             | 251        |
| 7.2.6    | Gonadotropin-Releasing Hormone Agonists and Antagonists                               | 251        |
| 7.2.6.1  | Gonadorelin                                                                           | 251        |
| 7.2.6.2  | Lupron (Leuprolide)                                                                   | 252        |
| 7.2.6.3  | Cetrorelix                                                                            | 253        |
| 7.2.6.4  | Degarelix                                                                             | 253        |
| 7.2.7    | Antihyperglycemics                                                                    | 254        |
| 7.2.7.1  | Symlin (Pramlintide)                                                                  | 254        |
| 7.2.7.2  | Exendin-4                                                                             | 254        |
| 7.2.7.3  | Liraglutide                                                                           | 255        |
| 7.2.8    | Icatibant                                                                             | 255        |
| 7.2.9    | Sermorelin                                                                            | 256        |
| 7.2.10   | Calcitonin                                                                            | 256        |
| 7.2.11   | Parathyroid Hormone                                                                   | 256        |
| 7.2.12   | Cyclosporine                                                                          | 257        |
| 7.2.13   | Fuzeon                                                                                | 257        |
| 7.3      | Approved Peptides in Oncology                                                         | 258        |
| 7.3.1    | Bortezomib                                                                            | 259        |
| 7.3.2    | Actinomycin D                                                                         | 259        |
| 7.3.3    | Marimastat                                                                            | 260        |
| 7.3.4    | Octreotide                                                                            | 260        |
| 7.3.5    | Vapreotide                                                                            | 261        |
| 7.3.6    | Octreoscan                                                                            | 262        |
| 7.4      | Antimicrobial peptides                                                                | 263        |
| 7.4.1    | Polymyxin                                                                             | 265        |
| 7.4.2    | Daptomycin                                                                            | 266        |
| 7.4.3    | Gramicidin S                                                                          | 267        |
| 7.5      | Perspectives                                                                          | 267        |
| 7.5.1    | Branched Peptides as Tumor-Targeting Agents                                           | 268        |
| 7.5.2    | Branched Peptides as Antimicrobials                                                   | 270        |
|          | References                                                                            | 271        |
| <b>8</b> | <b>Oral Bioavailability of Peptide and Peptidomimetic Drugs</b>                       | <b>277</b> |
|          | <i>Arik Dahan, Yasuhiro Tsume, Jing Sun, Jonathan M. Miller, and Gordon L. Amidon</i> |            |
| 8.1      | Introduction                                                                          | 277        |
| 8.2      | Fundamental Considerations of Intestinal Absorption                                   | 277        |
| 8.3      | Barriers Limiting Oral Peptide/Peptidomimetic Drug Bioavailability                    | 279        |
| 8.4      | Strategies to Improve Oral Bioavailability of Peptide-Based Drugs                     | 280        |
| 8.4.1    | Chemical Modifications                                                                | 280        |
| 8.4.1.1  | Prodrug Approach                                                                      | 280        |
| 8.4.1.2  | Structural Modifications                                                              | 281        |

|           |                                                                                                                                |            |
|-----------|--------------------------------------------------------------------------------------------------------------------------------|------------|
| 8.4.2     | Formulation Technologies                                                                                                       | 284        |
| 8.4.2.1   | Absorption Enhancers                                                                                                           | 284        |
| 8.4.2.2   | Coadministration with Protease Inhibitors                                                                                      | 285        |
| 8.4.2.3   | Formulation Vehicles                                                                                                           | 285        |
| 8.4.2.4   | Site-Specific Delivery                                                                                                         | 286        |
| 8.5       | Conclusions                                                                                                                    | 287        |
|           | References                                                                                                                     | 287        |
| <b>9</b>  | <b>Asymmetric Synthesis of <math>\beta</math>-Lactams via the Staudinger Reaction</b>                                          | <b>293</b> |
|           | <i>Monika I. Konaklieva and Balbina J. Plotkin</i>                                                                             |            |
| 9.1       | Introduction                                                                                                                   | 293        |
| 9.2       | Staudinger Reaction                                                                                                            | 293        |
| 9.3       | Influence of the Geometry of the Imine on Stereoselectivity in the Reaction                                                    | 294        |
| 9.4       | Influence of the Polarity of the Solvent on Stereoselectivity of the Reaction                                                  | 296        |
| 9.5       | Influence of the Isomerization of the Imine Prior to its Nucleophilic Attack onto the Ketene Stereoselectivity in the Reaction | 296        |
| 9.6       | Influence of the Order of Addition of the Reactants to the Reaction                                                            | 297        |
| 9.7       | Influence of Chiral Substituents on the Stereoselectivity of the Reaction                                                      | 298        |
| 9.8       | Asymmetric Induction from the Imine Component                                                                                  | 298        |
| 9.9       | Asymmetric Induction from the Ketene Component                                                                                 | 305        |
| 9.10      | Double Asymmetric Cycloinduction                                                                                               | 308        |
| 9.11      | Influence of Catalysts on the Stereoselectivity of the Reaction                                                                | 309        |
| 9.11.1    | General Procedure for $\beta$ -Lactams 106 with Proton Sponge                                                                  | 312        |
| 9.11.2    | General Procedure for the Tandem Nucleophile/Lewis Acid-Promoted Synthesis of $\beta$ -Lactams 110                             | 312        |
| 9.11.3    | General Procedure for Catalytic Asymmetric Synthesis of <i>Trans</i> - $\beta$ -Lactams 113                                    | 314        |
| 9.11.4    | Example for Kinugasa Reaction with Cu (II) Catalyst                                                                            | 316        |
| 9.11.4.1  | General Procedure for Catalytic Asymmetric Synthesis of $\beta$ -Lactams 122                                                   | 316        |
| 9.12      | Conclusions                                                                                                                    | 316        |
|           | References                                                                                                                     | 317        |
| <b>10</b> | <b>Advances in N- and O-Glycopeptide Synthesis – A Tool to Study Glycosylation and Develop New Therapeutics</b>                | <b>321</b> |
|           | <i>Ulrika Westerlind and Horst Kunz</i>                                                                                        |            |
| 10.1      | Introduction                                                                                                                   | 321        |
| 10.2      | Synthesis of O-Glycopeptides                                                                                                   | 324        |
| 10.2.1    | Synthesis of Mucin-Type Glycopeptides                                                                                          | 325        |

|            |                                                                                                                     |            |
|------------|---------------------------------------------------------------------------------------------------------------------|------------|
| 10.2.1.1   | Synthesis of Tumor-Associated Glycopeptides and Glycopeptide Vaccines                                               | 325        |
| 10.2.1.1.1 | Synthesis of Tn, T, Sialyl-Tn, and Sialyl-T Glycosylated Amino Acid Building Blocks                                 | 325        |
| 10.2.1.1.2 | Synthesis of Tn, T, Sialyl-Tn, and Sialyl-T Glycopeptides and Vaccines                                              | 329        |
| 10.2.1.2   | Synthesis of Glycopeptide Recognition Domain of P-Selectin Glycoprotein Ligand-1                                    | 331        |
| 10.2.1.2.1 | Synthesis of a Core 2 sLe <sup>x</sup> Amino Acid Building Block Including a sLe <sup>x</sup> Mimic                 | 332        |
| 10.2.1.2.2 | Synthesis of Unsulfated and Sulfated Core 2 sLe <sup>x</sup> and Core 2 sLe <sup>x</sup> Mimic PSGL-1 Glycopeptides | 334        |
| 10.2.1.2.3 | Chemoenzymatic Synthesis of Unsulfated and Sulfated sLe <sup>x</sup> PSGL-1 Glycopeptide                            | 336        |
| 10.2.2     | Synthesis of Other Types of O-Glycopeptides                                                                         | 339        |
| 10.2.2.1   | Synthesis of Fmoc-GlcNAc-Ser/Thr Amino Acids                                                                        | 340        |
| 10.2.2.2   | Synthesis of Estrogen Receptor Peptides for Conformational Analysis                                                 | 340        |
| 10.3       | Synthesis of N-Glycopeptides                                                                                        | 342        |
| 10.3.1     | Synthesis of RNase C Glycoprotein                                                                                   | 343        |
| 10.3.2     | Synthesis of Erythropoietin N-Glycopeptide Fragment 1–28                                                            | 346        |
| 10.3.2.1   | Synthesis of Biantennary Dodecasaccharide                                                                           | 346        |
| 10.3.2.2   | Synthesis of N-Glycopeptide Fragment 1–28                                                                           | 348        |
| 10.3.3     | Chemoenzymatic Synthesis of a HIV GP120 V3 Domain N-Glycopeptide                                                    | 350        |
| 10.3.3.1   | Synthesis of the Oxazoline Tetrasaccharide Donor                                                                    | 350        |
| 10.3.3.2   | Synthesis of Fmoc-GlcNAc-Asn Amino Acid Building Block                                                              | 351        |
| 10.3.3.3   | Synthesis of V3 Cyclic GlcNAc Peptide and Endo A Coupling with Man <sub>3</sub> GlcNAc Oxazoline Donor              | 352        |
|            | References                                                                                                          | 353        |
| <b>11</b>  | <b>Recent Developments in Neoglycopeptide Synthesis</b>                                                             | <b>359</b> |
|            | <i>Margaret A. Brimble, Nicole Miller, and Geoffrey M. Williams</i>                                                 |            |
| 11.1       | Introduction                                                                                                        | 359        |
| 11.2       | Neoglycoside and Neoglycopeptide Synthesis                                                                          | 361        |
| 11.2.1     | S-Glycosides                                                                                                        | 361        |
| 11.2.2     | N-Glycosides                                                                                                        | 362        |
| 11.2.3     | O-Glycosides                                                                                                        | 364        |
| 11.2.4     | C-Glycosides                                                                                                        | 365        |
| 11.2.5     | C=N Linkage                                                                                                         | 365        |
| 11.3       | Protein Side-Chain Modifications                                                                                    | 366        |
| 11.3.1     | Modifications of Cysteine Side-Chains                                                                               | 366        |
| 11.3.2     | Modifications of Lysine Side-Chains                                                                                 | 369        |
| 11.3.3     | Other Side-Chain Modifications                                                                                      | 370        |
| 11.4       | Cu(I)-Catalyzed Azide–Alkyne “Click” Cycloaddition                                                                  | 372        |

|          |                                                               |     |
|----------|---------------------------------------------------------------|-----|
| 11.4.1   | General Aspects of Cu(I)-Catalyzed Azide–Alkyne cycloaddition | 372 |
| 11.4.2   | Neoglycoside and Neoglycopeptide Synthesis via CuAAC          | 373 |
| 11.4.3   | CuAAC and Neoglycoproteins                                    | 376 |
| 11.5     | Cross-Metathesis                                              | 378 |
| 11.6     | Application of Neoglycopeptides as Synthetic Vaccines         | 380 |
| 11.7     | Enzymatic, Molecular, and Cell Biological Techniques          | 384 |
| 11.7.1.1 | Enzymatic Glycoprotein Synthesis                              | 385 |
| 11.7.2   | Molecular and Cell Biological Techniques                      | 385 |
|          | References                                                    | 386 |

### Part Three Amino Acids in Combinatorial Synthesis 393

|           |                                                                   |            |
|-----------|-------------------------------------------------------------------|------------|
| <b>12</b> | <b>Combinatorial/Library Peptide Synthesis</b>                    | <b>395</b> |
|           | <i>Michal Lebl</i>                                                |            |
| 12.1      | Introduction                                                      | 395        |
| 12.2      | High-Throughput Synthesis of Peptides                             | 396        |
| 12.2.1    | Parallel Peptide Synthesis                                        | 396        |
| 12.2.2    | Directed Sorting                                                  | 400        |
| 12.3      | Synthesis of Peptide Arrays                                       | 402        |
| 12.4      | Peptide Libraries                                                 | 406        |
| 12.4.1    | Synthesis of Peptide Mixtures                                     | 406        |
| 12.4.2    | Synthesis of Peptides on a Mixture of Particles                   | 409        |
| 12.4.2.1  | Determination of the Structure of a Peptide on an Individual Bead | 416        |
| 12.4.3    | Solution-Based Screening of OBOC Libraries                        | 418        |
| 12.5      | Future of Peptide Libraries                                       | 421        |
| 12.6      | Synthetic Protocols                                               | 421        |
| 12.6.1    | Pin Synthesis                                                     | 421        |
| 12.6.2    | SPOT Synthesis                                                    | 422        |
| 12.6.3    | Synthesis in Tea-Bags                                             | 422        |
| 12.6.4    | Synthesis on Cotton                                               | 423        |
| 12.6.4.1  | Modification of the Cotton Carrier                                | 423        |
| 12.6.5    | Split-and-Mix Synthesis of OBOC Noncleavable Libraries            | 424        |
| 12.6.6    | Preparation of Dual-Layer Beads                                   | 425        |
| 12.6.7    | Preparation of Library of Libraries                               | 426        |
| 12.6.8    | Preparation of OBOC Libraries for Testing in Solution             | 426        |
| 12.6.8.1  | Synthesis of Multicleavable Linker                                | 426        |
| 12.6.8.2  | Synthesis of the Library                                          | 428        |
| 12.6.8.3  | Quality Control of the Doubly Releasable Library                  | 428        |
| 12.6.8.4  | Two-Stage Release Assay in 96-Well Microassay Plates              | 429        |
| 12.6.9    | Synthesis of the Positional Scanning Library                      | 430        |

|           |                                                                                                 |            |
|-----------|-------------------------------------------------------------------------------------------------|------------|
| 12.6.10   | Synthesis of the Dual Defined Iterative Hexapeptide Library                                     | 430        |
| 12.6.11   | Acylation Monitoring by Bromophenol Blue                                                        | 431        |
|           | References                                                                                      | 432        |
| <b>13</b> | <b>Phage-Displayed Combinatorial Peptides</b>                                                   | <b>451</b> |
|           | <i>Renhua Huang, Kritika Pershad, Malgorzata Kokoszka, and Brian K. Kay</i>                     |            |
| 13.1      | Introduction                                                                                    | 451        |
| 13.1.1    | Types of Phage Vectors                                                                          | 452        |
| 13.1.2    | Generation of Combinatorial Peptide Libraries                                                   | 455        |
| 13.1.3    | Identifying Peptide Ligands to Protein Targets                                                  | 458        |
| 13.1.4    | Mapping Protein–Protein Interactions                                                            | 461        |
| 13.1.5    | Identifying Peptide Ligands Binding to Cell Surfaces                                            | 463        |
| 13.1.6    | Mapping Protease Specificity                                                                    | 464        |
| 13.1.7    | Identifying Peptide Ligands to the Surfaces of Inert Materials                                  | 464        |
| 13.2      | Conclusions                                                                                     | 465        |
|           | References                                                                                      | 466        |
| <b>14</b> | <b>Designing New Proteins</b>                                                                   | <b>473</b> |
|           | <i>Michael I. Sadowski and James T. MacDonald</i>                                               |            |
| 14.1      | Introduction                                                                                    | 473        |
| 14.1.1    | Why Design New Proteins?                                                                        | 473        |
| 14.1.2    | How New is “New?”                                                                               | 474        |
| 14.2      | Protein Design Methods                                                                          | 475        |
| 14.2.1    | Computational Design                                                                            | 476        |
| 14.2.1.1  | Computational Enzyme Design                                                                     | 477        |
| 14.2.1.2  | Results of Computational Design Experiments                                                     | 478        |
| 14.2.2    | Directed Evolution Methods                                                                      | 480        |
| 14.2.2.1  | Randomization Strategies                                                                        | 480        |
| 14.2.2.2  | Expression Systems and Assays                                                                   | 481        |
| 14.2.3    | Design of Protein Interfaces                                                                    | 482        |
| 14.3      | Protocol for Protein Design                                                                     | 484        |
| 14.4      | Conclusions                                                                                     | 486        |
|           | References                                                                                      | 487        |
| <b>15</b> | <b>Amino Acid-Based Dendrimers</b>                                                              | <b>491</b> |
|           | <i>Zhengshuang Shi, Chunhui Zhou, Zhigang Liu, Filbert Totsingan, and Neville R. Kallenbach</i> |            |
| 15.1      | Introduction                                                                                    | 491        |
| 15.2      | Peptide Dendrimer Synthesis: Divergent and Convergent Approaches                                | 491        |
| 15.2.1    | Synthesis of the First Peptide Dendrimers: Polylysine Dendrimers                                | 493        |
| 15.2.2    | Glutamic/Aspartic Acid, Proline, and Arginine Dendrimers                                        | 494        |

|        |                                                                               |     |
|--------|-------------------------------------------------------------------------------|-----|
| 15.2.3 | Synthesis of MAPs                                                             | 497 |
| 15.2.4 | Synthesis of Peptide Dendrimers Grafted on PAMAM and other Peptide Dendrimers | 500 |
| 15.3   | Applications of Peptide Dendrimers                                            | 502 |
| 15.3.1 | Initial Efforts on MAPs                                                       | 502 |
| 15.3.2 | Peptide Dendrimers as Antimicrobial Agents                                    | 502 |
| 15.3.3 | Peptide Dendrimers as Protein/Enzyme Mimics                                   | 504 |
| 15.3.4 | Peptide Dendrimers as Ion Sensors and MRI Contrast Agents                     | 505 |
| 15.3.5 | Peptide Dendrimers as DNA/RNA Delivery Vectors                                | 507 |
| 15.3.6 | Other Application of Peptide Dendrimers                                       | 512 |
| 15.4   | Conclusions                                                                   | 513 |
|        | References                                                                    | 514 |

|              |     |
|--------------|-----|
| <b>Index</b> | 519 |
|--------------|-----|